CASI Pharmaceuticals, Inc. Logo

CASI Pharmaceuticals, Inc.

Develops and commercializes drugs for oncology, transplant, and autoimmune disease.

CASI | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1701-1702, CHINA CENTRAL OFFICE TOWER 1, 100025 BEIJING
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company's primary clinical development program centers on CID-103, an investigational anti-CD38 monoclonal antibody. This therapy is being developed to treat antibody-mediated rejection (AMR) in organ transplant recipients and for various autoimmune diseases, addressing a significant unmet medical need. In addition to its research and development pipeline, CASI maintains a portfolio of commercialized pharmaceutical products, primarily targeting the oncology market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CASI Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CASI Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CASI Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060

Talk to a Data Expert

Have a question? We'll get back to you promptly.